The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukaemia.

This study was published in Blood Cancer Discovery, a journal of the American Association for Cancer Research

Senior author of this study was Charalambos Andreadis, MD, professor of clinical medicine at the University of California, San Francisco (UCSF), and first author was Victoria Wang, MD, PhD, an assistant professor of haematology and oncology at UCSF.

“Only about half of patients with acute myeloid leukaemia (AML) will achieve long-term disease control,” said Andreadis.

Patients whose AML relapses or does not respond to initial therapy have worse outcomes, Andreadis explained.

These patients typically undergo subsequent multi-agent chemotherapy, a toxic treatment with limited success in this population, he added.

“Unfortunately, patients whose cancers relapse or don’t respond to initial therapy face a poor outlook, as only 30 to 40 percent of these patients respond to subsequent multi-agent chemotherapy and even fewer develop long-term remissions.

Most patients will eventually succumb to their disease,” he said.

New therapies targeting AML-specific mutations have been developed in recent years; however, these target select patients, highlighting the need for new, widely applicable therapies, according to Andreadis.

In their study, Andreadis and colleagues evaluated the safety and efficacy of an investigational agent targeting a shared chemical pathway in combination with single-agent chemotherapy in patients with relapsed/refractory AML.

The investigational therapy, ficlatuzumab, is a first-in-class monoclonal antibody that binds the extracellular hepatocyte growth factor (HGF) to prevent it from activating MET signalling and stimulating tumour growth.

“Unlike most existing targeted cancer therapies, ficlatuzumab targets an extracellular factor instead of a cancer-specific mutation,” Andreadis noted, adding that some patients with refractory AML have higher levels of circulating HGF.

The phase I clinical trial enrolled 17 adult patients with AML that was either refractory to prior treatment or that had relapsed within 12 months of prior treatment. Patients received four doses of ficlatuzumab, administered 14 days apart, along with the chemotherapeutic cytarabine.

Results: Nine of 17 patients (53 percent) had a complete response, and four of the responding patients had no signs of minimal residual disease.

Among responding patients, the progression-free survival was 31.2 months, and the overall survival was not reached. Ten patients (eight responders and two non-responders) proceeded to allogeneic haematopoietic cell transplantation; six of these patients remained in remission at the most recent follow-up.

The most common adverse event was febrile neutropenia. Serious adverse events occurred in two patients, and there was one death unrelated to the investigational therapy.

To identify molecular changes associated with treatment response, Andreadis and colleagues analysed peripheral blood mononuclear cells collected at baseline and at several timepoints after treatment initiation.

They found that ficlatuzumab treatment led to attenuated phosphorylation of MET, the receptor for HGF, thereby confirming on-target inhibition of HGF.

Clinical response to ficlatuzumab treatment was associated with reduced phosphorylation of the S6 protein and increased expression of genes involved in myeloid and leukocyte activation, whereas non-responding patients were more likely to have increased expression of HGF, increased phosphorylation of S6, and expression of genes involved in protein translation, cell adhesion, and type I interferon signalling.

“The 53 percent response rate was quite striking to us since historical response rates for the standard-of-care treatment are in the 30 percent range,” noted Andreadis.

“While these results need to be validated in a larger study, they suggest that ficlatuzumab in combination with single-agent chemotherapy may lead to better responses with less toxicity in patients with relapsed/refractory AML.”

“By comparing pre-treatment to post-treatment blood samples using state-of-the art single-cell mass cytometry and RNA sequencing, we observed that ficlatuzumab successfully suppressed HGF signalling, and we also identified biomarkers of treatment response and resistance,” said Wang.

“This approach provided novel insight into the molecular changes that occur upon treatment, which could have clinical implications for tracking treatment response or identifying patients likely to respond.”

“Together, our findings suggest that targeting an extracellular factor in conjunction with existing cancer therapies could be an effective therapeutic strategy for AML treatment,” said Andreadis.

Limitations of the study include the small sample size and its single-arm design.

Andreadis and Wang noted that since the study was designed to assess safety and dosing, rather than efficacy, additional studies to validate the efficacy findings will be needed.

A phase II clinical trial to evaluate ficlatuzumab plus chemotherapy has been initiated. An additional limitation was the lack of bone marrow specimens for the gene expression analyses.

The study was supported by the National Cancer Institute, the Damon Runyon Postdoctoral Award, the American Society for Clinical Oncology Young Investigator Award, the Department of Defense, and a Gateway for Cancer Grant. Andreadis and Wang declare no conflicts of interest.

Source: American Association for Cancer Research (AACR)